Clinical outcomes of First-line Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Deprivation Therapy (ADT) + Docetaxel (D) or ADT alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

BACKGROUND: The CHAARTED and STAMPEDE trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abirater...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Genitourin Cancer
Hauptverfasser: Francini, Edoardo, Yip, Steven, Ahmed, Shubidito, Li, Haocheng, Ardolino, Luke, Evan, Carolyn P., Kaymakcalan, Marina, Shaw, Grace K., Kantoff, Philip W., Taplin, Mary-Ellen, Alimohamed, Nimira S., Joshua, Anthony M., Heng, Daniel Y. C., Sweeney, Christopher J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986287/
https://ncbi.nlm.nih.gov/pubmed/29331381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.12.012
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge